References

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 178 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Tracking Antibiotic-Resistant Tuberculosis. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Tracking Antibiotic-Resistant Tuberculosis (online CE course)
References

Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership [The Lancet Infectious Diseases Web site]. June 2013;13(6):529-539. Accessed May 12, 2022. http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(13)70030-6/fulltext
Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9153 patients. PLOS Med. August 28, 2012; 9(8) e1001300. Accessed May 12, 2022. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001300.
Barrera L. The basics of clinical bacteriology. In: Palomino JC, Leao SC, Ritacco V, eds. Tuberculosis 2007:From basic science to patient care. 1st ed. San Paulo: 93-112. Accessed May 12, 2022. http://www.pneumo-iasi.ro/student/tuberculosis2007.pdf.
Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Eng J Med. September 9, 2010; 363:1005-1015. Accessed May 12, 2022. http://www.nejm.org/doi/full/10.1056/NEJMoa0907847.
Brazier B, McShane H. Towards new TB vaccines. Semin Immunopathol. 2020;42(3):315-331. doi:10.1007/s00281-020-00794-0
Cegielski P, Nunn P, Kurbatova, EV, et al. Challenges and controversies in defining totally drug-resistant tuberculosis. Centers for Disease Control and Prevention [Web site]. November 2012;18(11). Accessed May 12, 2022. http://wwwnc.cdc.gov/eid/article/18/11/12-0526_article.htm.
Centers for Disease Control and Prevention (CDC). Drug-Resistant TB. CDC website. Oct. 2021. Accessed May 11, 2022. https://www.cdc.gov/tb/statistics/reports/2020/drug_resistant.htmmsclkid=6b5844c0d15011ecb7bded6084adf972
Centers for Disease Control and Prevention (CDC) Fact Sheets 2016. BCG vaccine. Accessed May 12, 2022. www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm.
Centers for Disease Control and Prevention (CDC) Fact Sheets 2016. Interferon-gamma release assays (IGRAs)- blood tests for TB infection. MMWR. 2010;59 (No.RR-5). Accessed May 12, 2022. www.cdc.gov/tb/publications/factsheets/testing/igra.htm.
Centers for Disease Control and Prevention (CDC) Fact Sheets 2020. The Costly Burden of Drug-Resistant TB in the U.S. 2020. Accessed May 12, 2022. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/costly-burden-dr-tb-508.pdf
Centers for Disease Control and Prevention (CDC). Trends in tuberculosis—United States 2021. Morbity and Mortality Weekly Report (MMWR). March 25, 2022;71(12):441-446. Accessed May 12, 2022. https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7112a1-H.pdf.
Filia A, Ciarrocchi G, Belfiglio R, et al. Tuberculosis in kindergarten and primary school, Italy, 2008-2009 [dispatch]. Centers for Disease Control and Prevention [Web site]. March 2011;17(3). Accessed May 12, 2022. http://wwwnc.cdc.gov/eid/article/17/3/10-1440_article.htm.
Fitzgerald D, Haas DW. Mycobacterium tuberculosis. In: Mandel, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, PA: Elsevier Inc; Updated 2020.
Garfein RS, Laniado-Laborin R, Rodwell TC, et al. Latent tuberculosis among persons at risk for infection with HIV, Tijuana, Mexico [research]. Centers for Disease Control and Prevention [Web site]. May 2010;16(5). Accessed May 12, 2022. http://wwwnc.cdc.gov/eid/article/16/5/09-1446_article.htm.
Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Accessed May 12, 2022. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1.
Lee SH. Tuberculosis Infection and Latent Tuberculosis. Tuberc Respir Dis (Seoul). 2016;79(4):201-206. doi:10.4046/trd.2016.79.4.201
Lin S-Y, Probert W, et al. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons. J Clin Microbiol. September 2004;42(9):4204. Accessed May 12, 2022. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC516347/.
McKinnon J. Budget cuts hit TB clinics at the border. Associated Press, California Health Report. April 2, 2012.
Migliori G, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany [letter]. Emerg Infect Dis. Centers for Disease Control and Prevention [Web site]. May 2007;13(5). Accessed May 12, 2022. http://wwwnc.cdc.gov/eid/article/13/5/07-0200_article.htm.
Parrish NM, Carroll KC. Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low -prevalence settings. Jour Clin Microbiol. March 2011;49(3): 772-776. Accessed May 12, 2022. http:="" www.ncbi.nlm.nih.="" gov="" pmc="" articles="" pmc3067741="" ?="" report="reader.
Pfyffer GE. Mycobacterium: General characteristics, laboratory detection, and staining procedures. In: Carroll KC, Pfaller, MA. Manual of Clinical Microbiology, 12th ed. Washington, DC: ASM Press; 2019.
Phillips L. Infectious disease: TB’s revenge. Nature. January 2, 2013;493:14-16. Accessed May 12, 2022. http://www.nature.com/news/infectious-disease-tb-s-revenge-1.12115.
Pinon M, Scolfaro C, Bignamini E, et al. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics. November 1, 2010;126(5):e1253-e1256. Accessed May 12, 2022. http://pediatrics.aappublications.org/content/126/5/e1253.full.
Richter E, Brown-Elliott BA, Wallace Jr. RJ, et al. Mycobacterium: Laboratory characteristics of slowly growing mycobacteria. In: Carroll KC, Pfaller MA. Manual of Clinical Microbiology, 12th ed. Washington, DC: ASM Press; 2019.
Russell DG, Cardona PJ, Kim MJ, et al. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol. September 2009;10(9):943-948. Accessed May 12, 2022. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759071/.
StopTBPartnership. The Paradigm Shift 2018-2022. 2015. Accessed May 14, 2022. https://www.stoptb.org/sites/default/files/gpr_2018-2022_digital.pdf
TuBerculosis Vaccine Initiative (TBVI). What we do: Pipeline of vaccines. 2022. Accessed May 14, 2022. https://www.tbvi.eu/what-we-do/pipeline-of-vaccines/
Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax [serial online]. 2012; 67(4). Accessed May 12, 2022. http://thorax.bmj.com/content/67/4/286.extract.
Udwadia ZF, Amale RA, Ajbani KK, et al. Totally drug-resistant tuberculosis in India [correspondence]. Clin Infect Dis. 2012; 54(4):579-581. Accessed May 12, 2022. http://cid.oxfordjournals.org/content/54/4/579.long.
Udwadia ZF. Totally drug-resistant tuberculosis in India: Who let the djinn out? [editorial]. Respirology 2012;17:741-742. DOI: 10.1111/j.1440-1843.2012.02192.x
United Nations. Sustainable Development Goals. UN.org website. September, 2018. Accessed May 14, 2022. https://www.un.org/sustainabledevelopment/blog/2018/09/who-calls-for-urgent-action-to-end-tb/
Woods GL, Lin S-Y G, Desmond EP. Susceptibility test methods: Mycobacteria, Nocardia, and other Actinomycetes. In: In: Carroll KC, Pfaller MA, Manual of Clinical Microbiology, 12th ed. Washington, DC: ASM Press; 2019.
World Health Organization (WHO). Estimated incidence of MDR/RR Tuberculosis (TB) in 2019. WHO website, March 2021. Accessed May 13, 2022. https://publichealthmaps.org/motw-2021/2021/3/24/24-march-2021-estimated-incidence-of-mdr-rr-tuberculosis-tb-in-2019.
World Health Organization (WHO). Global Tuberculosis Report 2021, pg 28. 2021. Accessed May 11. 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021
World Health Organization (WHO). Tuberculosis: Drug-resistant tuberculosis (XDR-TB). Jan. 2018. Accessed May 12, 2022. https://www.who.int/news-room/questions-and-answers/item/tuberculosis-extensively-drug-resistant-tuberculosis-(XDR-TB)?msclkid=64848cb8d14d11ec84d5625f3b7d61ba
World Health Organization (WHO). Tuberculosis. World Health Organization website. Oct. 14, 2021. Accessed May 12, 2022. https://www.who.int/news-room/fact-sheets/detail/tuberculosis